Some items on our site have recently moved. Visit our News Hub for selected articles, special reports, podcasts and other resources.
Illumina’s $7.1 billion play for cancer startup Grail faces global headwinds
16 April 2021 00:00
On March 30, the US Federal Trade Commission challenged Illumina’s proposed acquisition of cancer diagnostic startup Grail, arguing that Illumina would have both the incentive and the ability to disadvantage Grail’s competitors by denying them access to its essential, next-generation sequencing technology. The deal has tapped into global regulatory concerns over vertical acquisitions, pharmaceutical deals and so-called killer acquisitions.
US Federal Trade Commission’s lawsuit to block Illumina’s acquisition of Grail contains ominous portents.
Illumina’s outrage at an attempt by the European Commission to capture a non-notifiable deal is a sign of the kind of backlash that a revision might bring.